{"cursor":"8973","size":15,"audio":[],"currentlang":"en","article":"{{Infobox company\n| company_name = Genmab A/S company_logo = company_type = Publicly traded\n| Aktieselskab traded_as = foundation = 1999 location = Copenhagen, Denmark\n| key_people = Jan Van de Winkel (President and CEO) , Michael\n| Widmer (Chairman) industry = Biotechnology products =\n| Pharmaceuticals, antibodies revenue = DKK 582 million\n| (2010) operating_income = (DKK 498.0\n| million) (2009) net_income = (DKK 1.011\n| billion) (2009) num_employees = 310\n| (2009) intl = yes homepage =\n| [http://www.genmab.com/ www.genmab.com]\n}}\n\n'Genmab A/S' is a Danish biotechnology company, founded in February 1999 by\nBankInvest Biomedical venture fund lead by Florian SchÃ¶nharting. http://www.sec.gov/Archives/edgar/data/874255/0000950130-99-\n001225.txt Genmab is based in Copenhagen. Internationally, it operates\nthrough the subsidiaries 'Genmab BV' in Utrecht, The Netherlands, and 'Genmab,\nInc' in Princeton, New Jersey, USA. The Company is publicly traded on the NASDAQ\nOMX Copenhagen A/S. [https://www.nasdaqomxnordic.com/aktier/shareinformatio-\nn?Instrument=CSE11143] Genmab expanded with an antibody manufacturing\nfacility in Brooklyn Park, Minnesota, USA in 2008, which it now plans to close.\n'Genmab's Technology' is licensed from Medarex to create fully human high\naffinity antibodies using transgenic mice. These antibodies are less likely to\nelicit an allergic reaction and other side effects compared with other types of\nmanmade antibodies containing other animal proteins because the IgG antibodies\nproduced have human proteins. This technology is called the HuMab-Mouse\ntechnology. One benefit of using this type of technology is that there is no\nneed for humanization or complicated genetic engineering to make this antibody\nfit for humans which cuts down on expenses and time spent developing it. It can\nbe generated within months and can be selected to bind to specific antigens such\nas tumor cells and other infectious agents. Genmab also has developed its own\ntechnology called UniBody, which is used to make smaller antibodies in contrast\nto the traditional full sized monoclonal antibody. Its smaller size allows for\nbetter distribution over larger target areas like tumors. The UniBody can only\nbind to one site and doesnât elicit a harmful immune response by binding to two\nsites and over-activating cell growth. It does not kill target cells but rather\nsilences or inhibits them. Thus it can be used to treat certain cancers,\ninflammations, allergies and asthmas, where killing the cell isnât the\nobjective. [http://www.genmab.com/en/About%20Genmab/About-\n%20Genmab.aspx] The technology modifies the human IgG4 antibody. Normally\nthe IgG4 is considered inert and doesnât elicit an immune response. However,\nthey are also unstable and fall apart easily, which makes them unsuitable for\ntherapeutic settings. Genmab changes the shape of the IgG4 antibody by\neliminated the hinge, the part of the antibody that creates the âYâ shape. This\nhalves the antibody, creating a smaller version now known as their UniBody. This\nsmaller version can only bind to one site and does not stimulate cancer cells to\ngrow. [http://www.genmab.com/Science%20And%20Research/Next%20Generation%20T-\nechnology.aspx]\n","linknr":156,"url":"Genmab","recorded":1376425798,"links":["/w/index.php?title=Genmab&action=edit","/w/index.php?title=Genmab&action=edit","//bits.wikimedia.org/favicon/wikipedia.ico","/w/opensearch_desc.php","//en.wikipedia.org/w/api.php?action=rsd","//creativecommons.org/licenses/by-sa/3.0/","/w/index.php?title=Special:RecentChanges&feed=atom","http://en.wikipedia.org/wiki/Genmab","//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&lang=en&modules=ext.gadget.DRN-wizard%2CReferenceTooltips%2Ccharinsert%2Cteahouse%7Cext.rtlcite%2Cwikihiero%7Cext.uls.nojs%7Cmediawiki.legacy.commonPrint%2Cshared%7Cmw.PopUpMediaTransform%7Cskins.vector&only=styles&skin=vector&*","//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&lang=en&modules=ext.visualEditor.viewPageTarget.noscript&only=styles&skin=vector&*","//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&lang=en&modules=site&only=styles&skin=vector&*","//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&lang=en&modules=startup&only=scripts&skin=vector&*","//bits.wikimedia.org/geoiplookup","//meta.wikimedia.org","#mw-navigation","#p-search","/wiki/File:Genmab.svg","//upload.wikimedia.org/wikipedia/en/thumb/3/33/Genmab.svg/180px-Genmab.svg.png","/wiki/Types_of_business_entity","/wiki/Public_company","/wiki/Aktieselskab","/wiki/Ticker_symbol","/wiki/OMX","http://www.nasdaqomxnordic.com/shares/shareinformation?Instrument=CSE11143","/wiki/Biotechnology","/wiki/Copenhagen","/wiki/Denmark","/wiki/Chief_executive_officer","/wiki/Chairman_(official)","/wiki/Drug","/wiki/Antibody","/wiki/Danish_krone","#cite_note-AR2009-1","/wiki/Earnings_before_interest_and_taxes","//upload.wikimedia.org/wikipedia/commons/thumb/e/ed/Decrease2.svg/11px-Decrease2.svg.png","#cite_note-AR2009-1","/wiki/Net_income","//upload.wikimedia.org/wikipedia/commons/thumb/e/ed/Decrease2.svg/11px-Decrease2.svg.png","#cite_note-AR2009-1","#cite_note-AR2009-1","http://www.genmab.com/","/wiki/Denmark","/wiki/Biotechnology_company","#cite_note-2","/wiki/Copenhagen","/wiki/Utrecht_(city)","/wiki/The_Netherlands","/wiki/Princeton,_New_Jersey","/w/index.php?title=NASDAQ_OMX_Copenhagen_A/S&action=edit&redlink=1","#cite_note-3","/wiki/Medarex","#cite_note-genmab.com-4","#cite_note-5","#History_of_the_Company","#Partnerships","#Research_pipeline","#References","#External_links","/w/index.php?title=Genmab&action=edit&section=1","/w/index.php?title=Genmab&veaction=edit&section=1","/wiki/Medarex","/wiki/Donald_L._Drakeman","/wiki/Biotechnology_Industry_Organization","#cite_note-6","/wiki/James_D._Watson","#cite_note-7","#cite_note-8","/w/index.php?title=Genmab&action=edit&section=2","/w/index.php?title=Genmab&veaction=edit&section=2","/w/index.php?title=Genmab&action=edit&section=3","/w/index.php?title=Genmab&veaction=edit&section=3","/w/index.php?title=Genmab&action=edit&section=4","/w/index.php?title=Genmab&veaction=edit&section=4","#cite_ref-AR2009_1-0","#cite_ref-AR2009_1-1","#cite_ref-AR2009_1-2","#cite_ref-AR2009_1-3","http://www.genmab.com/~/media/1Corporate%20Documents/Genmab_UK_web.ashx","#cite_ref-2","http://www.sec.gov/Archives/edgar/data/874255/0000950130-99-001225.txt","#cite_ref-3","https://www.nasdaqomxnordic.com/aktier/shareinformation?Instrument=CSE11143","#cite_ref-genmab.com_4-0","http://www.genmab.com/en/About%20Genmab/About%20Genmab.aspx","#cite_ref-5","http://www.genmab.com/Science%20And%20Research/Next%20Generation%20Technology.aspx","#cite_ref-6","http://www.lilsi.org/","#cite_ref-7","http://www.bio.org/news/pressreleases/newsitem.asp?id=2005_0224_01","#cite_ref-8","http://www.genmab.com/~/media/1Corporate%20Documents/Genmab_Uk_web.ashx","/w/index.php?title=Genmab&action=edit&section=5","/w/index.php?title=Genmab&veaction=edit&section=5","http://www.genmab.com","//en.wikipedia.org/w/index.php?title=Special:CentralAutoLogin/start&type=1x1&from=enwiki","http://en.wikipedia.org/w/index.php?title=Genmab&oldid=565895756","/wiki/Help:Category","/wiki/Category:Pharmaceutical_companies_of_Denmark","/wiki/Category:Biotechnology_companies_of_Denmark","/wiki/Category:Life_science_companies_based_in_Copenhagen","/wiki/Category:Companies_established_in_1999","/w/index.php?title=Special:UserLogin&returnto=Genmab&type=signup","/w/index.php?title=Special:UserLogin&returnto=Genmab","/wiki/Genmab","/wiki/Talk:Genmab","#","/wiki/Genmab","/w/index.php?title=Genmab&action=edit","/w/index.php?title=Genmab&veaction=edit","/w/index.php?title=Genmab&action=history","#","/w/index.php","//bits.wikimedia.org/static-1.22wmf12/skins/vector/images/search-ltr.png?303-4","/wiki/Main_Page","/wiki/Main_Page","/wiki/Portal:Contents","/wiki/Portal:Featured_content","/wiki/Portal:Current_events","/wiki/Special:Random","https://donate.wikimedia.org/wiki/Special:FundraiserRedirector?utm_source=donate&utm_medium=sidebar&utm_campaign=C13_en.wikipedia.org&uselang=en","/wiki/Help:Contents","/wiki/Wikipedia:About","/wiki/Wikipedia:Community_portal","/wiki/Special:RecentChanges","//en.wikipedia.org/wiki/Wikipedia:Contact_us","/wiki/Special:WhatLinksHere/Genmab","/wiki/Special:RecentChangesLinked/Genmab","/wiki/Wikipedia:File_Upload_Wizard","/wiki/Special:SpecialPages","/w/index.php?title=Genmab&oldid=565895756","/w/index.php?title=Genmab&action=info","//www.wikidata.org/wiki/Q2076526","/w/index.php?title=Special:Cite&page=Genmab&id=565895756","/w/index.php?title=Special:Book&bookcmd=book_creator&referer=Genmab","/w/index.php?title=Special:Book&bookcmd=render_article&arttitle=Genmab&oldid=565895756&writer=rl","/w/index.php?title=Genmab&printable=yes","//da.wikipedia.org/wiki/Genmab","//ru.wikipedia.org/wiki/Genmab","//sv.wikipedia.org/wiki/Genmab","#","//www.wikidata.org/wiki/Q2076526#sitelinks-wikipedia","//en.wikipedia.org/wiki/Wikipedia:Text_of_Creative_Commons_Attribution-ShareAlike_3.0_Unported_License","//creativecommons.org/licenses/by-sa/3.0/","//wikimediafoundation.org/wiki/Terms_of_Use","//wikimediafoundation.org/wiki/Privacy_policy","//www.wikimediafoundation.org/","//wikimediafoundation.org/wiki/Privacy_policy","/wiki/Wikipedia:About","/wiki/Wikipedia:General_disclaimer","//en.wikipedia.org/wiki/Wikipedia:Contact_us","//en.m.wikipedia.org/wiki/Genmab","//wikimediafoundation.org/","//bits.wikimedia.org/images/wikimedia-button.png","//www.mediawiki.org/","//bits.wikimedia.org/static-1.22wmf12/skins/common/images/poweredby_mediawiki_88x31.png","//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&lang=en&modules=site&only=scripts&skin=vector&*"],"instances":["city","official"],"pdf":[],"categories":["Pharmaceutical companies of Denmark","Biotechnology companies of Denmark","Life science companies based in Copenhagen","Companies established in 1999"],"headings":["History of the Company","Partnerships","Research pipeline","References","External links"],"image":["//upload.wikimedia.org/wikipedia/en/thumb/3/33/Genmab.svg/180px-Genmab.svg.png","//upload.wikimedia.org/wikipedia/commons/thumb/e/ed/Decrease2.svg/11px-Decrease2.svg.png","//upload.wikimedia.org/wikipedia/commons/thumb/e/ed/Decrease2.svg/11px-Decrease2.svg.png","//en.wikipedia.org/w/index.php?title=Special:CentralAutoLogin/start&type=1x1&from=enwiki","//bits.wikimedia.org/static-1.22wmf12/skins/vector/images/search-ltr.png?303-4","//bits.wikimedia.org/images/wikimedia-button.png","//bits.wikimedia.org/static-1.22wmf12/skins/common/images/poweredby_mediawiki_88x31.png"],"tags":[["chairman","official"],["utrecht","city"]],"members":["utrecht","chairman"],"related":["Public_company","Aktieselskab","Copenhagen","Denmark","Chief_executive_officer","Chairman_(official)","Biotechnology","Drug","Antibody","Danish_krone","Denmark","Biotechnology_company","Copenhagen","Utrecht_(city)","The_Netherlands","Princeton,_New_Jersey","NASDAQ_OMX_Copenhagen_A/S","Medarex","Medarex","Donald_L._Drakeman","Biotechnology_Industry_Organization","James_D._Watson"]}